Moran Wealth Management LLC Sells 1,645 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Moran Wealth Management LLC cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.6% in the second quarter, HoldingsChannel.com reports. The fund owned 7,687 shares of the medical research company’s stock after selling 1,645 shares during the period. Moran Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $4,011,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Bank Julius Baer & Co. Ltd Zurich grew its stake in shares of Thermo Fisher Scientific by 100,798.8% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 406,539,228 shares of the medical research company’s stock worth $212,111,842,000 after acquiring an additional 406,136,310 shares during the period. BlackRock Inc. grew its stake in shares of Thermo Fisher Scientific by 2.1% during the 1st quarter. BlackRock Inc. now owns 31,423,285 shares of the medical research company’s stock valued at $18,111,439,000 after purchasing an additional 633,163 shares during the period. Morgan Stanley grew its stake in shares of Thermo Fisher Scientific by 17.7% during the 4th quarter. Morgan Stanley now owns 11,730,063 shares of the medical research company’s stock valued at $6,459,629,000 after purchasing an additional 1,764,312 shares during the period. FMR LLC grew its stake in shares of Thermo Fisher Scientific by 1.7% during the 1st quarter. FMR LLC now owns 11,354,044 shares of the medical research company’s stock valued at $6,544,130,000 after purchasing an additional 194,602 shares during the period. Finally, Moneta Group Investment Advisors LLC grew its stake in shares of Thermo Fisher Scientific by 104,536.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 8,355,245 shares of the medical research company’s stock valued at $4,601,150,000 after purchasing an additional 8,347,260 shares during the period. 87.06% of the stock is currently owned by institutional investors.

Insider Activity

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $456.15, for a total value of $4,561,500.00. Following the completion of the transaction, the chief executive officer now directly owns 131,175 shares in the company, valued at $59,835,476.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 3,000 shares of the business’s stock in a transaction dated Wednesday, August 30th. The shares were sold at an average price of $557.77, for a total value of $1,673,310.00. Following the completion of the transaction, the executive vice president now directly owns 17,556 shares in the company, valued at $9,792,210.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $456.15, for a total value of $4,561,500.00. Following the transaction, the chief executive officer now directly owns 131,175 shares in the company, valued at $59,835,476.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,000 shares of company stock worth $10,778,910. 0.32% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

TMO has been the subject of several recent research reports. TheStreet lowered Thermo Fisher Scientific from a “b-” rating to a “c+” rating in a report on Monday, November 6th. Royal Bank of Canada cut their price target on Thermo Fisher Scientific from $657.00 to $579.00 and set an “outperform” rating for the company in a report on Thursday, October 26th. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Thursday, October 26th. Barclays dropped their target price on shares of Thermo Fisher Scientific from $625.00 to $585.00 in a report on Friday, September 29th. Finally, Stifel Nicolaus dropped their target price on shares of Thermo Fisher Scientific from $660.00 to $530.00 and set a “buy” rating for the company in a report on Thursday, October 26th. Two analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $593.94.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $469.03 on Tuesday. The company has a 50 day moving average price of $478.08 and a 200-day moving average price of $513.60. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.25 and a current ratio of 1.63. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $609.85. The company has a market capitalization of $181.22 billion, a PE ratio of 30.74, a P/E/G ratio of 2.87 and a beta of 0.81.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $5.69 EPS for the quarter, beating the consensus estimate of $5.61 by $0.08. Thermo Fisher Scientific had a net margin of 13.68% and a return on equity of 18.88%. The business had revenue of $10.57 billion during the quarter, compared to analyst estimates of $10.60 billion. During the same quarter in the previous year, the business posted $5.08 EPS. The company’s quarterly revenue was down 1.0% compared to the same quarter last year. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a stock buyback plan on Tuesday, November 14th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 2.2% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, January 16th. Stockholders of record on Friday, December 15th will be issued a $0.35 dividend. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $1.40 annualized dividend and a dividend yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.17%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.